Columbia University

Wigen Biomedicine Technology (Shanghai) Co., Ltd.

Soochow University

Wigen Boimedicine Technology (Shanghai) Co., Ltd.

Wigen Biomedicine Technology Co., Ltd.

Yuli Xie

Donald W Landry

Houxing Fan

Shi-Xian Deng

Lihui Qian

Gangli Gong

Gang Cao

Kirsten Alison Rinderspacher

Yidong Liu

Jeremy Robert Greenwood

Hualiang Jiang

Kaixian Chen

Cheng Luo

Leah Lynn Frye

Yuanyuan Zhang

Richard Ambron

Ying-Ju Sung

Zhiyi Yao

Liyan Yue

Wei Wan

Paul Harris

Antonella Maffei

Shixian Deng

Gerard Karsenty

Bing Zhou

Patricia F Ducy

Shi Xian Deng

Vijay Kumar Yadav

Bidong Zhang

Yidong Lu

K Alison Rinderspacher

Yingming Wu

The invention relates to a series of new pyrrole compounds and preparation methods and uses thereof. Specifically, the present invention relates to compounds as shown in general formula (1) and the preparation method thereof, and the uses of the compound shown in general formula (1) and optical isomers, crystal forms and pharmaceutically acceptable salts in preparation of drugs for prevention or treatment of diseases related to fungal infection.

Pyrrole compounds useful as antifungals

The present invention relates to a spiro ring-containing quinazoline compound, a preparation method therefor, and use of the compound as a K-Ras G12C inhibitor in preparing antitumor medicaments.

Spiro ring-containing quinazoline compounds

The present invention relates to a compound of general formula (1) and a preparation method therefor, and use of the compound of formula (1) and isomers, crystalline forms and pharmaceutically acceptable salts thereof as an irreversible inhibitor for a K-Ras G12C mutant protein in preparing a medicament for resisting Ras-related diseases such as tumors.

Spiro ring-containing quinazoline compound

The invention relates to a type of novel pyridine compound and a preparation method and application thereof. Specifically, the invention relates to a compound of formula (1) and a preparation method thereof, and an application of the compound of formula (1) and pharmaceutically acceptable salts thereof as aurora kinase inhibitors in preparation of anti-tumor drugs.

Aurora kinase inhibitors and uses thereof

Aurora kinase inhibitors and use thereof

Disclosed in the present invention are compounds as MYT1 inhibitors. Particularly, the present invention relates to compounds represented by general formula (1) and a preparation method therefor, as well as the use of the compounds of general formula (1), and isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates thereof as MYT1 inhibitors. The compounds of the present invention as well as the isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates thereof can be used for preparing drugs for treating or preventing diseases related to MYT1 protein.

Compounds as MYT1 inhibitors

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, a preparation method and application thereof. The compounds can selectively inhibit the activity of epidermal growth factor receptor (EGFR) mutants, and shows good inhibitory effect towards mutant EGFR and anti-proliferative activity against cancer cells. Thus they can be used for treating tumors and related diseases.

Compounds for inhibiting EGFR kinase, preparation methods and uses thereof

It is related to compounds used as autophagy modulators and a method for preparing and using the same, specifically providing a compound of general formula (I), or pharmaceutically acceptable salts thereof, which is a type of autophagy modulators, particularly mammalian ATG8 homologues modulators. 

Compound used as autophagy regulator, and preparation method therefor and uses thereof

The invention relates to a series of novel compounds containing acryloyl group. In particular, the invention relates to acryloyl group-containing compounds shown in formula (1) and the preparation method thereof, and application of the compounds shown in formula (1) and pharmaceutically acceptable salts thereof in preparation of medicaments for treating, regulating and/or preventing diseases related to physiological conditions related to CRM1 protein. 

Acryloyl-containing nuclear transport regulators and uses thereof

The present invention provides an isoindolone-imide ring-1,3-dione-2-ene compound, and a preparation method, a pharmaceutical composition and use thereof. Specifically, the present invention provides a compound of Formula (I) below or a pharmaceutically acceptable salt thereof, wherein Ar is an isoindolinone-imide group represented by Formula (II), L is absent or is a divalent, trivalent or tetravalent linking group, and X is a group represented by Formula (III). Definitions of the other groups are as described in the specification. The compound of Formula (I) is an autophagy modulators, particularly a mammalian ATG8 homolog modulator. 

Class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof

The present invention relates to compounds that exhibit vasodilatory and anti-inflammatory effects by inhibiting the activity of soluble epoxide hydrolase (sEH). The present invention is also directed to methods of identifying such compounds, and use of such compounds for the treatment of diseases related to dysfunction of vasodilation, inflammation, and/or endothelial cells. In particular non-limiting embodiments, components of the invention may be used to treat hypertension.

Potent non-urea inhibitors of soluble epoxide hydrolase

The present invention relates to compounds that may be used to inhibit activation of protein kinase G ('PKG'). It is based, at least in part, on the discovery of the tertiary structure of PKG and the identification of molecules that either bind to the active site of PKG and/or are analogs of balanol.

Neuronal pain pathway modulators

The present invention provides, inter alia, a compound of formula I: wherein the substituent designations are indicated in the Specification. The present invention also provides pharmaceutical compositions comprising a compound of formula I, and methods of treatment or prevention of diabetes or hyperglycemia in a patient, and of normalizing blood glucose levels in a subject, by administering an effective amount of a compound of formula I. 

Hypoglycemic dihydropyridones

Potent non-urea inhibitors of soluble epdxide hydrolase

The present invention provides, inter alia, dihydropyridone compounds and compositions, including analogs of a vesicular monoamine transporter type 2 (VMAT2) antagonist. The present invention also provides methods of using such compounds/analogs for modulating glucose levels, and/or preventing, treating, or ameliorating the effects of diabetes and hyper-glycemia.

Glucose metabolism modulating compounds

Growing community of inventors

Shanghai, China

Yuli Xie